CALA Stock Price, Calithera Biosciences Quote, Chart

Market Summary

USD0.020.00

Delayed

0.00%

CALA Stock Price

View Fullscreen

CALA RSI Chart

CALA Valuation

Market Cap

146.2K

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0.01

Price/Free Cashflow

0

CALA Price/Sales (Trailing)

CALA Profitability

Free Cashflow Yield

-29.9K%

CALA Fundamentals

CALA Revenue

CALA Earnings

Breaking Down CALA Revenue

Last 90 days

-33.3%

Trailing 12 Months

-33.3%

How does CALA drawdown profile look like?

CALA Financial Health

CALA Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	0	4.4M	10.3M	9.9M
2020	0	2.0M	2.1M	0
2019	0	17.8M	1.6M	0
2018	27.0M	36.8M	29.5M	22.3M
2017	0	0	0	26.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Calithera Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 27, 2023	pakianathan deepika	sold	-46,358	0.3858	-120,161	-
Jan 27, 2023	pakianathan deepika	sold	-452	0.3858	-1,172	-
Jan 23, 2023	wong stephanie	sold (taxes)	-141	0.4461	-317	see remarks
Jan 23, 2023	sjogren eric	sold (taxes)	-124	0.4461	-279	sr. vp, drug discovery
Jan 23, 2023	molineaux christopher	sold (taxes)	-96.8037	0.4461	-217	sr. vp, development
Jan 23, 2023	molineaux susan	sold (taxes)	-234	0.4461	-526	president & ceo
Jan 23, 2023	kuriakose emil	sold (taxes)	-35.2419	0.4461	-79.00	chief medical officer
Jan 21, 2022	kuriakose emil	sold (taxes)	-327	0.4915	-666	chief medical officer
Jan 21, 2022	parlati francesco	sold (taxes)	-2,356	0.4915	-4,794	sr. vp, research
Jan 21, 2022	sjogren eric	sold (taxes)	-2,356	0.4915	-4,794	sr. vp, drug discovery

Which funds bought or sold CALA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Feb 14, 2024	Coppell Advisory Solutions LLC	sold off	-100	-2,201	-	-%
Feb 14, 2023	Axiom Investment Management LLC	sold off	-100	-	-	-%
Jul 15, 2022	Cordasco Financial Network	new	-	-	-	-%
Nov 15, 2021	Marshall Wace North America L.P.	new	-	670,000	670,000	-%
Nov 15, 2021	Delphi Management Partners VIII, L.L.C.	unchanged	-	218,000	5,290,000	3.82%
Aug 13, 2021	QS Investors, LLC	new	-	279,000	279,000	-%

Are Funds Buying or Selling CALA?

Are funds buying CALA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CALA

No. of Funds

Unveiling Calithera Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 26, 2023	takeda pharmaceutical co ltd	0.0%	0	SC 13D/A
Feb 14, 2023	biotechnology value fund l p	5.7%	276,601	SC 13G/A
Feb 14, 2023	citadel advisors llc	5.1%	6	SC 13G/A
Feb 09, 2023	primecap management co/ca/	8.24%	401,080	SC 13G/A
Feb 09, 2023	primecap management co/ca/	4.11%	199,963	SC 13G/A
Feb 08, 2023	incyte corp	0%	0	SC 13G/A
Dec 08, 2022	primecap management co/ca/	8.35%	406,280	SC 13G/A
Jul 06, 2022	takeda pharmaceutical co ltd	15.00%	857,844	SC 13D/A
Apr 21, 2022	takeda pharmaceutical co ltd	13.2%	14,817,484	SC 13D
Apr 11, 2022	citadel advisors llc	5.3%	6	SC 13G

Calithera Biosciences Inc News

Latest updates

Calithera Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2020Q3	2020Q2	2019Q3	2019Q2	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-100.0%	-	6,750,000	3,000,000	167,000	361,000	834,000	760,000	-	-	17,065,000	5,189,000	7,254,000	7,254,000	7,255,000	4,192,000
Operating Expenses	286.6%	69,209,000	17,900,000	17,307,000	22,901,000	20,752,000	21,127,000	24,912,000	20,224,000	19,507,000	20,803,000	19,001,000	18,796,000	13,907,000	12,990,000	9,948,000
S&GA Expenses	-27.6%	4,594,000	6,344,000	4,487,000	4,744,000	5,096,000	3,906,000	3,984,000	3,247,000	3,087,000	3,498,000	3,508,000	3,300,000	3,074,000	2,848,000	3,308,000
R&D Expenses	-100.0%	-	11,556,000	12,820,000	18,157,000	15,656,000	17,221,000	20,928,000	16,977,000	16,420,000	17,305,000	15,493,000	15,496,000	10,833,000	10,142,000	6,640,000
EBITDA Margin	-Infinity%	-11.77	-	-	-56.34	-35.69	-6.60	-4.07	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	725,000	658,000	663,000	606,000	568,000	582,000	541,000	169,000
EBT Margin	-Infinity%	-11.80	-	-	-58.45	-37.03	-7.02	-4.33	-	-	-	-	-	-	-	-
Net Income	-519.5%	-69,210,000	-11,172,000	-14,311,000	-22,734,000	-20,391,000	-20,293,000	-24,152,000	-19,499,000	-18,849,000	-3,075,000	-13,206,000	-10,974,000	-6,071,000	-5,194,000	-5,587,000
Net Income Margin	-283.8%	-11.80	-3.08	-3.60	-4.01	-3.90	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-235.2%	-25,611,000	-7,641,000	-11,157,000	-16,313,000	-17,995,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Assets	-22.7%	29.00	37.00	46.00	50.00	65.00	90.00	98.00	111	126	148	165	150	169	146	166	132	143	148	159	179	192
Current Assets	-23.3%	27.00	35.00	43.00	47.00	61.00	86.00	94.00	107	119	140	157	138	160	137	156	121	140	145	145	156	168
Cash Equivalents	-25.3%	25.00	34.00	42.00	45.00	60.00	84.00	92.00	101	107	121	115	40.00	60.00	22.00	77.00	41.00	51.00	61.00	56.00	55.00	48.00
Net PPE	-8.8%	0.00	0.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00
Liabilities	-22.5%	8.00	11.00	10.00	13.00	16.00	16.00	15.00	16.00	23.00	25.00	22.00	22.00	26.00	26.00	27.00	26.00	16.00	12.00	12.00	31.00	42.00
Current Liabilities	-20.0%	7.00	9.00	9.00	11.00	14.00	14.00	12.00	14.00	18.00	20.00	16.00	16.00	20.00	19.00	19.00	18.00	15.00	11.00	11.00	30.00	39.00
Shareholder's Equity	-22.7%	20.00	26.00	35.00	-	8.00	74.00	83.00	94.00	102	123	143	128	142	121	139	106	127	136	147	148	150
Retained Earnings	-1.4%	-512	-505	-495	-505	-491	-422	-410	-396	-376	-353	-330	-310	-286	-264	-244	-219	-196	-176	-157	-154	-150
Additional Paid-In Capital	0.2%	511	510	509	502	500	497	494	491	479	476	474	438	428	385	383	326	323	313	305	303	301
Shares Outstanding	0.1%	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	3.00	4.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	12.00	-	-	-	143	-	-	-	345	-	-	-	189	-	-	-	154	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Cashflow From Operations	-11.1%	-8,598	-7,736	-11,274	-16,000	-25,572	-7,605	-11,121	-22,002	-23,001	-16,301	-17,995	-27,015	-18,395	-19,676	-20,050	-20,624	-13,888	-16,562	-19,440	-14,952	-11,363
Share Based Compensation	-0.3%	936	939	975	1,180	2,348	2,577	2,644	2,695	1,884	2,117	2,066	1,993	1,458	1,530	1,795	1,683	1,820	1,816	1,920	1,881	1,568
Cashflow From Investing	-Infinity%	-23.00	-	-	-	-39.00	-108	1,500	6,500	9,065	21,986	58,523	-614	15,154	-35,208	274	8,996	-4,595	16,135	20,091	21,168	18,659
Cashflow From Financing	-73.3%	4.00	15.00	8,499	1,137	655	1.00	475	9,537	500	2.00	33,900	7,659	42,017	-247	55,984	1,154	8,406	5,692	378	150	1,768

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CALA Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue		$ 9,750
Type of Revenue [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 28,533	$ 53,455	$ 71,015
Research and development related to asset acquisition		50,875
General and administrative	13,541	20,853	20,372
Total operating expenses	42,074	125,183	91,387
Loss from operations	(42,074)	(115,433)	(91,387)
Other income (expense):
Transaction costs allocable to warrant liabilities	(475)
Change in fair value of warrant liabilities	2,422
Interest and other income, net	477	345	1,250
Other income (expense), net	2,424	345	1,250
Net loss	(39,650)	(115,088)	(90,137)
Deemed contribution from Series A preferred stock extinguishment	18,360
Net loss attributable to common stockholders - basic	$ (21,290)	$ (115,088)	$ (90,137)
Net loss per share attributable to common stockholders - basic	$ (4.60)	$ (31.16)	$ (26.20)
Net loss per share attributable to common stockholders - diluted	$ (7.94)	$ (31.16)	$ (26.20)
Weighted average common shares used to compute net loss per share attributable to common stockholders - basic	4,633	3,693	3,441
Weighted average common shares used to compute net loss per share attributable to common stockholders - diluted	4,992	3,693	3,441

CALA Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 25,451	$ 59,537
Prepaid expenses and other current assets	1,173	1,915
Total current assets	26,624	61,452
Restricted cash	270	270
Property and equipment, net	434	556
Operating lease right-of-use asset	1,348	2,478
Total assets	28,676	64,756
Current liabilities:
Accounts payable	732	3,650
Accrued and other liabilities	6,658	10,356
Total current liabilities	7,390	14,006
Noncurrent operating lease liability	136	1,666
Warrant liabilities	758
Total liabilities	8,284	15,672
Commitments and contingencies
Convertible preferred stock; $0.0001 par value; 10,000 shares authorized as of December 31, 2022 and 2021; 0 and 1,000 shares issued and outstanding as of December 31, 2022 and 2021, respectively; $35,000 liquidation preference as of December 31, 2022 and 2021 (Note 6)		40,702
Stockholders’ equity:
Convertible preferred stock; $0.0001 par value; 10,000 shares authorized as of December 31, 2022 and 2021; 1,000 and 0 shares issued and outstanding as of December 31, 2022 and 2021, respectively; $35,000 liquidation preference as of December 31, 2022 and 2021 (Note 6)	22,342
Common stock, $0.0001 par value, 200,000 shares authorized as of December 31, 2022 and 2021, 4,868 and 3,857 shares issued and outstanding as of December 31, 2022 and 2021, respectively
Additional paid-in capital	510,666	499,708
Accumulated deficit	(512,616)	(491,326)
Total stockholders’ equity	20,392	8,382
Total liabilities, convertible preferred stock and stockholders' equity	$ 28,676	$ 64,756

About Calithera Biosciences Inc

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

CEO	Dr. Susan M. Molineaux Ph.D.
WEBSITE	calithera.com
INDUSTRY	Biotechnology
EMPLOYEES	8

Calithera Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Calithera Biosciences Inc? What does CALA stand for in stocks?

CALA is the stock ticker symbol of Calithera Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Calithera Biosciences Inc (CALA)?

As of Thu May 16 2024, market cap of Calithera Biosciences Inc is 146.18 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CALA stock?

You can check CALA's fair value in chart for subscribers.

What is the fair value of CALA stock?

You can check CALA's fair value in chart for subscribers. The fair value of Calithera Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Calithera Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CALA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Calithera Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CALA is over valued or under valued. Whether Calithera Biosciences Inc is cheap or expensive depends on the assumptions which impact Calithera Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CALA.

What is Calithera Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, CALA's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CALA PE ratio will change depending on the future growth rate expectations of investors.